Breaking News Instant updates and real-time market news.

2017-07-24 12:24:41

EVHC

Envision Healthcare

$61.80

-0.81 (-1.29%)

12:24

07/24/17

07/24

12:24

07/24/17

12:24

Yale researchers point to Envision unit for inflating ER bills, NY Times says

Researchers at Yale state in a newly published study that the rate of out-of-network doctor's bills for customers of one large insurer jumped when EmCare, part of publicly traded Envision Healthcare, entered a hospital, according to The New York Times. In a statement to the Times, EmCare called the study "fundamentally flawed and dated," adding that the issue of surprise billing was not specific to any one company, and that it had already publicly committed to reaching agreements with insurers for the majority of its doctors within the next two years. Reference Link

08

Aug

23

Aug

EVHCEnvision Healthcare

$61.80

-0.81 (-1.29%)

06/27/17

RBCM

06/27/17NO CHANGERBCM

Envision Healthcare merger positive, says RBC Capital

After meeting with Envision's management, RBC Capital analyst Frank Morgan says he's "comfortable with the strategy behind" its merger with Amsurg Corp. The analyst thinks that the combined company "has the right model for the future of hospital-based medicine." He is upbeat on the company's longer term outlook and raised his price target o t he name to $77 from $72 while keeping an Outperform rating.

05/03/17

ADAM

05/03/17NO CHANGETarget $68ADAMBuy

Envision Healthcare price target lowered to $68 from $86 at Canaccord

Canaccord analyst Richard Close lowered his price target on Envision Healthcare to $68 from $86 but tells investors to remain patient through the post-merger strategic review and softer volume environment as the cross-sell of physician services is successful. Close maintained his Buy rating on Envision Healthcare shares.

05/03/17

BARD

05/03/17NO CHANGETarget $73BARDOutperform

Envision Healthcare Q1 results better than feared, says Baird

Baird analyst Whit Mayo said Envision Healthcare's Q1 results were better than feared as he believes its less than 2% guide-down to core growth should put the stock higher. The company valuation is below the industry, setting up the stock well for Q2. Mayo lowered his price target to $73 from $81 on Envision Healthcare shares but reiterated his Outperform rating.

04/21/17

JEFF

04/21/17NO CHANGETarget $75JEFFBuy

Jefferies sees risk to Envision's guidance, cuts target to $75

With pre-releases from HCA Holdings (HCA) and MEDNAX (MD) highlighting payor mix challenges, Jefferies analyst Brian Tanquilut sees risk to Envision Healthcare's (EVHC) guidance. Snowstorms in March and payor mix pressure were likely not fully baked into Envision's Q1 outlook, Tanquilut tells investors in a research note. The analyst expects a "modest" Q1 EBITDA miss. He lowered his price target for Envision shares to $75 from $82 but keeps a Buy rating on the name. The stock's significant decline since Feb. 28 already reflects expectations for a miss and guidance cut, the analyst contends.

AT&T Mobility has reached a tentative agreement with the Communications Workers of America in Mobility Orange contract negotiations. The four-year agreement, which will be submitted to the union's membership for a ratification vote in coming days, covers about 20,000 employees in 36 states and the District of Columbia - AT&T's Mobility Orange unit, which encompasses CWA Districts 1, 2-13, 4, 7 and 9.

Pfizer announced that the United States FDA has approved IXIFI, a chimeric human-murine monoclonal antibody against tumor necrosis factor, as a biosimilar to Remicade for all eligible indications of the reference product. The FDA has approved IXIFI as a treatment for patients with rheumatoid arthritis, Crohn's disease, pediatric Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

Western Alliance Bancorporation announced that during the first quarter of 2018 Robert Sarver will transition from Chairman and CEO to Executive Chairman. In conjunction with Sarver's change in role, Ken Vecchione will be promoted to Chief Executive Officer, Dale Gibbons to Vice Chairman and Chief Financial Officer, and James Haught to President and Chief Operating Officer, all effective April 1, 2018.

Aqua America announced that President and CEO Christopher H. Franklin has been elected chairman of the board, effective Jan. 1, 2018. Franklin became CEO in July 2015 and has served on the board of directors since October 2015. He succeeds Nicholas DeBenedictis, former CEO, who will continue to serve on the board as chairman emeritus.